Publications by authors named "J W Kylstra"
Article Synopsis
- The study investigates how using medication samples of anti-VEGF agents affects future treatment choices in patients with neovascular age-related macular degeneration (nvAMD) while waiting for prior authorizations.
- Researchers compared nvAMD patients who received sample medications (ranibizumab or aflibercept) with those who did not to assess the impact on drug selection and visual outcomes over time.
- Results showed high adherence to initial medication choices in both groups, with significantly lower usage of bevacizumab and higher usage of aflibercept among those who received samples across multiple injections and at one-year follow-up.
A simple eye model for practicing indirect ophthalmoscopy and retinal laser photocoagulation.
Digit J Ophthalmol
January 2019
Purpose: To describe a simple and inexpensive model eye that allows lifelike simulation of indirect ophthalmoscopy and retinal photocoagulation.
Methods: A 60 D examination lens, a bulb syringe, foam poster-board, a manila folder, a hobby knife, a fine pair of scissors, a glue gun, and a 2.5 cm square Optos color fundus photograph printed at 1200 dpi resolution on glossy photographic paper were used to create a model eye.
SPONTANEOUS CLOSURE OF A MACULAR HOLE AFTER FOUR FAILED VITRECTOMIES IN THE SETTING OF NF-1.
Retin Cases Brief Rep
February 2018
Purpose: To present the case of a patient who developed spontaneous closure of an idiopathic macular hole after four failed attempts at surgical closure.
Methods: This is a retrospective case review of the medical record of a single patient. No statistical analysis was performed.
Purpose: To describe an unusual case of frosted branch angiitis that developed in a patient with acute onset systemic vasculitis possibly triggered by the antithyroid medication methimazole.
Methods: We conducted a thorough review of the medical records of a 16-year-old female patient who presented with frosted branch angiitis. During the initial hospital admission, the patient underwent an extensive systemic workup to determine the etiology of her disease and ophthalmologic testing including fundus photographs and fluorescein angiography.
Purpose: Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission.
Patients And Methods: Patients with CD20(+) stage III or IV FL with complete response (CR), unconfirmed CR (CRu), or partial response (PR) after first-line induction treatment were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2) days -7 and 0, then (90)Y-ibritumomab 14.